Serum Resistin, Cardiovascular Disease and All-Cause Mortality in Patients with Type 2 Diabetes

Abstract

BackgroundHigh serum resistin has been associated with increased risk of cardiovascular disease in the general population, Only sparse and conflicting results, limited to Asian individuals, have been reported, so far, in type 2 diabetes. We studied the role of serum resistin on coronary artery disease, major cardiovascular events and all-cause mortality in type 2 diabetes.MethodsWe tested the association of circulating resistin concentrations with coronary artery disease, major cardiovascular events (cardiovascular death, non-fatal myocardial infarction and non-fatal stroke) and all-cause mortality in 2,313 diabetic patients of European ancestry from two cross-sectional and two prospective studies. In addition, the expression of resistin gene (RETN) was measured in blood cells of 68 diabetic patients and correlated with their serum resistin levels.ResultsIn a model comprising age, sex, smoking habits, BMI, HbA1c, and insulin, antihypertensive and antidyslipidemic therapies, serum resistin was associated with coronary artery disease in both cross-sectional studies: OR (95%CI) per SD increment = 1.35 (1.10–1.64) and 1.99 (1.55–2.55). Additionally, serum resistin predicted incident major cardiovascular events (HR per SD increment = 1.31; 1.10–1.56) and all-cause mortality (HR per SD increment = 1.16; 1.06–1.26). Adjusting also for fibrinogen levels affected the association with coronary artery disease and incident cardiovascular events, but not that with all cause-mortality. Finally, serum resistin was positively correlated with RETN mRNA expression (rho = 0.343).ConclusionsThis is the first study showing that high serum resistin (a likely consequence, at least partly, of increased RETN expression) is a risk factor for cardiovascular disease and all-cause mortality in diabetic patients of European ancestry.

Increased resistin may suppress reactive oxygen species production and inflammasome activation in type 2 diabetic patients with pulmonary tuberculosis infection

“…Human resistin, however, is not only an adipokine leading to insulin resistance, but also an inflammatory mediator. Recent studies showed that resistin is an inflammatory marker for the development of atherosclerosis in diabetic patients [7]. These findings strongly suggested that resistin may be one of the linkages between type 2 DM and chronic inflammation.…”

Diabetic Cardiomyopathy. Resistin: A Control of a Myocardial Hypertrophy

“…За счет ремоделирования сердце имеет возможность поддерживать внешнюю ра-ботоспособность на клинически приемлемом уровне [6]. Ремоделирование затрагивает основные механизмы функционирования миокарда, в том числе и кардио-миоцит-фибробластые связи, регулирующие обмен со-единительных белков сердечной мышцы.…”

The Association between Serum Resistin Levels and Major Adverse Cardiac Events

“…In contrast, Erer et al showed the association of high baseline resistin levels with an increased risk of MACE and resistin was found to be an independent risk factor for predicting MACE in patients with AMI [19]. In a study, systemic review and meta-analysis, Fontana et al analyzed data from Gargano Heart Study (GHS) which was prospective in nature, to investigate the association between resistin and both all cause and cardiovascular (CV) mortality risk [20] [21]. There was 7 studies (n = 4016; 961 events) for all-cause mortality and 6 studies (n = 4187; 961 events) for CV mortality in this meta-analysis.…”